1. Home
  2. Live Updates
  3. Ezh2

Live Breaking News & Updates on Ezh2

Stay informed with the latest breaking news from Ezh2 on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ezh2 and stay connected to the pulse of your community

Unmet Needs in Treating Relapsed/Refractory FL

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Bijal-shah , Laurie-sehn , Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Fl , Ctdna , Pod-24 , Ezh2 , Tumor-microenvironment , Immunotherapy

Tazemetostat as Third-line and Beyond Therapy for FL

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Peter-martin , Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Beyond-therapy , Third-line-and-beyond , Third-line-treatment , Tazemetostat , Fl , Fl-treatment , Follicular-lymphoma-treatment

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer

The FDA has granted fast track designation to tulmimetostat for use as a potential therapeutic option in patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and whose disease had progressed on at least 1 prior line of therapy.

Tim-demuth , Fda , Tulmimetostat , Fast-track-designation , Endometrial-cancer , Gynecologic-cancer , Ezh2 , Ezh2-inhibitor , Asco , Cpi-0209 ,